Characterization of unique ADTN-catecholamine binding sites in the iris root-ciliary body of rabbits

A binding site for tritiated 2-amino-6, 7-dihydroxy-1, 2,3,4-tetrahydronaphthalene (ADTN) has been partially characterized in the rabbit iris root-ciliary body. Binding of ADTN is proportional to protein content and requires at least 60 minutes to reach equilibrium. Binding is saturable, with a Kd of 27 +/- 1 nM and a Bmax of 2.1 +/- .3 pmol/mg protein (mean +/- SEM). Dopamine competes for this site with a Ki of 100 nM and apomorphine with a Ki of 180 nM. This site is not blocked by L-timolol, phenoxybenzamine, or by several DA1 and DA2 antagonists. It appears to be a new type of catecholamine binding site, of a type not observed outside the anterior eye. It is possible that some of the effects of dopamine on intraocular pressure are mediated through this binding site.     

Remission and Recovery in the Treatment for Adolescents With Depression Study (TADS): Acute and Long-Term Outcomes

ObjectiveWe examine remission rate probabilities, recovery rates, and residual symptoms across 36 weeks in the Treatment for Adolescents with Depression Study (TADS).MethodThe TADS, a multisite clinical trial, randomized 439 adolescents with major depressive disorder to 12 weeks of treatment with fluoxetine, cognitive–behavioral therapy, their combination, or pill placebo. The pill placebo group, treated openly after week 12, was not included in the subsequent analyses. Treatment differences in remission rates and probabilities of remission over time are compared. Recovery rates in remitters at weeks 12 (acute phase remitters) and 18 (continuation phase remitters) are summarized. We also examined whether residual symptoms at the end of 12 weeks of acute treatment predicted later remission.ResultsAt week 36, the estimated remission rates for intention-to-treat cases were as follows: combination, 60%; fluoxetine, 55%; cognitive–behavioral therapy, 64%; and overall, 60%. Paired comparisons reveal that, at week 24, all active treatments converge on remission outcomes. The recovery rate at week 36 was 65% for acute phase remitters and 71% for continuation phase remitters, with no significant between-treatment differences in recovery rates. Residual symptoms at the end of acute treatment predicted failure to achieve remission at weeks 18 and 36.ConclusionsMost depressed adolescents in all three treatment modalities achieved remission at the end of 9 months of treatment.     

Management of hydrocephalus in children with plasminogen deficiency.

Congenital plasminogen deficiency is an infrequent disorder, which usually becomes symptomatic as ligneous conjunctivitis. However, pseudomembranous lesions in the mucosa of the pharynx, tracheobronchial tree, and the peritoneum may likewise occur. An accompanying hydrocephalus is extremely rare; only 16 cases have been reported to date. The reports indicate that hydrocephalus, even if treated by ventriculoperitoneal (VP) cerebrospinal fluid (CSF) shunting, worsens the prognosis substantially. Thus, VP CSF shunting does not seem to be the optimal therapy for hydrocephalic children with plasminogen deficiency. We add two cases to the literature, and, on the base of our experience, we propose a management strategy for the hydrocephalus. We report the case history of two children with plasminogen deficiency and associated hydrocephalus. Both children initially were treated with VP shunts and had a very similar clinical course with multiple shunt malfunctions due to nonabsorption by the peritoneum. In the first child, the attempt to treat the hydrocephalus with a ventriculoatrial (VA) shunt failed due to catheter thrombosis. Finally, a ventriculocholecystic shunt was placed in both children, which worked well. In patients with plasminogem deficiency and associated hydrocephalus, special care must be taken in the management of hydrocephalus. The absorptive capacity of the peritoneum is reduced by pseudomembrane formation, which results in VP shunt malfunction. The plasminogen deficiency results in early thrombus formation if atrial catheters are used. Therefore, the authors believe that ventriculocholecystic shunting should be considered early on in the course of the disease.     

Arbeitsgemeinschaft Urologische Onkologie (AUO) in der Deutschen Krebsgesellschaft e.V.

Zusammenfassung Mit derzeit knapp 85.000 uroonkologischen Neuerkrankungen pro Jahr stellt die Uroonkologie einen wesentlichen Bestandteil in der urologischen Tätigkeit dar. Am 29. Juni 1989 wurde die Arbeitsgemeinschaft Urologische Onkologie (AUO) in der Deutschen Krebsgesellschaft gegründet, um diesem Teilgebiet die notwendige Aufmerksamkeit widmen zu können. Bereits zur Gründung steckte sich die AUO das hohe Ziel, Forschungstätigkeit in der Uroonkologie unter einem Dach zu versammeln und für eine hohe Qualität klinischer Studien zu sorgen.     

The prognostic value of somatosensory and motor evoked potentials in comatose patients.

Somatosensory and motor evoked potentials (SEP and MEP) were examined in a total of 213 patients in traumatic (n = 140) and nontraumatic (n = 73) coma. It was the aim of this study to compare the prognostic value of MEP elicited by both electrical and magnetoelectric transcranial stimulation with the use of SEP alone. According to the presence or absence of responses and the duration of central conduction time, SEP and MEP obtained during Days 1 through 3 after the onset of coma were divided into four categories and correlated with the outcome of the patients, as assessed by the Glasgow Outcome Scale. Our results clearly show that in terms of prognostic value, SEP are superior to MEP, with normal findings indicating a favorable outcome and absent responses an unfavorable outcome. On the other hand, patients with normal electromyographic responses after both electrical and magnetoelectric stimulation had favorable and unfavorable outcomes about equally. Thus, unlike SEP, normal MEP do not allow any prognostic conclusions. Only the bilateral absence of MEP in response to electrical stimulation was a definitely unfavorable prognostic sign because all of these patients died. In contrast, with magnetoelectric stimulation, neither normal nor absent responses allowed any prognostic conclusions. Therefore, the prognostic value of electrically evoked motor responses is limited, and magnetoelectric stimulation cannot be recommended in this context.